A Phase 3 interventional study of NBI-1065845 and Placebo in Major Depressive Disorder, sponsored by Neurocrine Biosciences. Recruiting at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Depressive Disorder, Major by Neurocrine Biosciences — 6 open to participants now, 6 under way, 5 of them phase 3. Depressive Disorder, Major · Neurocrine Biosciences.
Among the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2025, is one of 5 in phase 3, and was the 6th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →6 of the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences are open now, in 12 countries. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
Neurocrine Biosciences · Sites in United States, Australia, Bulgaria and 8 more countries
Ages 18+
Neurocrine Biosciences · Sites in United States, Belgium, Canada and 4 more countries
Ages 18+
Neurocrine Biosciences · Sites in United States, Australia, Belgium and 20 more countries
Ages 18+
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 200 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 192 across the 10 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
3 of the studies in Depressive Disorder, Major by Neurocrine Biosciences that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06911112Phase 3Neurocrine BiosciencesNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT06963021Phase 3Neurocrine BiosciencesNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT06786624Phase 3Neurocrine BiosciencesStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Depressive Disorder, Major by Neurocrine Biosciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Key Inclusion Criteria:
Key Exclusion Criteria:
NBI-1065845 administered orally once a day.
Drug: NBI-1065845
Placebo identical in appearance to NBI-1065845 will be administered orally once a day.
Drug: Placebo
NBI-1065845 tablets
Also known as: TAK-653
Matching placebo tablets
Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56
Time frame: Baseline, Day 56
Change from Baseline in Sheehan Disability Scale (SDS) Total Score at Day 56
Time frame: Baseline, Day 56
Change from Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Day 56
Time frame: Baseline, Day 56
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jul 2027, 28 months after the start.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 28 months is close to that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osavampator